Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Batmunkh Tsetsegsaikhan, Neal Eleanor F G, Amraa Otgonjargal, Mazarakis Nadia, Altangerel Bolor, Avaa Naranbaatar, Batbayar Lkhagvagaram, Batsukh Khishigjargal, Bright Kathryn, Burentogtokh Tsogjargal, Do Lien Anh Ha, Dorj Gantuya, Hart John D, Jamiyandorj Otgonbold, Javkhlantugs Khulan, Jigjidsuren Sarantsetseg, Justice Frances, Li Shuo, Mashbaatar Khaliunaa, Moore Kerryn A, Namjil Narantuya, Nguyen Cattram Duong, Ochirbat Batbayar, Surenjav Unursaikhan, Thomson Helen, Tsolmon Bilegtsaikhan, Licciardi Paul V, von Mollendorf Claire, Mulholland Kim
Аннотация
METHODS: In this randomised, controlled, non-inferiority trial, adults primed with two doses of ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were randomised (1:1) to receive a 15 μg (fractional dose) or 30 μg (standard dose) BNT162b2 booster. Geometric mean ratios (GMR) of IgG and surrogate virus neutralising test (sVNT) levels (Wuhan-Hu-1 and Omicron BA.1) were compared over 12 months. SARS-CoV-2 infections, and adverse and serious adverse events (SAEs), were documented.
CLINICALTRIALS: gov Identifier: NCT05265065.
RESULTS: Of 601 participants randomised between May 27th and September 30th, 2022, 2 (0.3 %) were lost to follow-up and 19 (3.2 %) withdrew by 12 months. IgG levels declined from 28 days to six months, stabilising thereafter. At 12 months, IgG levels were lower in the fractional compared with the standard arm for ChAdOx1-S primed participants (GMR 0.78 [95 % CI 0.63-0.96], p = 0.017). At six and 12 months, the median sVNT inhibition percentages were comparable by study arm and priming strata. Documented SARS-CoV-2 infections occurred in 25 participants (fractional dose arm n = 12; standard dose arm n = 13). From 28 days, 228 undocumented infections (≥ 1.2-fold IgG increase) occurred (fractional arm n = 112; standard arm n = 116). SAEs (n = 41) were balanced between arms, with no severe vaccine-related AEs or SAEs reported.
CONCLUSIONS: 15 μg and 30 μg BNT162b2 boosters demonstrated comparable immunogenicity and favourable safety. 15 μg BNT162b2 booster doses may improve vaccine acceptability due to lower reactogenicity.